|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Chandana SR and Conley BA: Neoadjuvant
chemotherapy for locally advanced squamous cancers of the head and
neck: current status and future prospects. Curr Opin Oncol.
21:218–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen EE, Lingen MW and Vokes EE: The
expanding role of systemic therapy in head and neck cancer. J Clin
Oncol. 22:1743–1752. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pfister DG, Ang KK, Brizel D, et al: NCCN
Practice Guidelines in Oncology, Head and Neck Cancers, Version
2.2011. National Comprehensive Cancer Network®; 2011
|
|
5
|
Brockstein B, Haraf DJ, Rademaker AW, et
al: Patterns of failure, prognostic factors and survival in
locoregionally advanced head and neck cancer treated with
concomitant chemoradiotherapy: a 9-year, 337-patient,
multi-institutional experience. Ann Oncol. 15:1179–1186. 2004.
|
|
6
|
Posner MR, Hershock DM, Blajman CR, et al
TAX 324 Study Group: Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vermorken JB, Remenar E, van Herpen C, et
al EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and
docetaxel in unresectable head and neck cancer. N Engl J Med.
357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beitler JJ and Cooper JS: Seduction by
induction? J Clin Oncol. 27:9–10. 2009. View Article : Google Scholar
|
|
9
|
Haddad RI and Posner MR: Induction
chemotherapy in head and neck cancer. J Clin Oncol. 27:e52–e53.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen EW, Karrison T, Kocherginsky M,
Huang C, Agulnik M, Mittal B, Yunus F, Samant S, Brockstein B, Raez
L, Mehra R, Kumar P, Ondrey F, Seiwert T, Villaflor V, Haraf D and
Vokes E: DeCIDE: A phase III randomized trial of docetaxel (D),
cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC)
in patients with N2/N3 locally advanced squamous cell carcinoma of
the head and neck (SCCHN). J Clin Oncol. 30(Suppl): abstr 5500.
2012.PubMed/NCBI
|
|
11
|
Haddad RI, Rabinowits G, Tishler RB,
Adkins D, Khuri FR, Clark J, Lorch JH, Limaye SA, Wirth LJ, O’Neill
A, Riley S and Posner MR: The PARADIGM trial: A phase III study
comparing sequential therapy (ST) to concurrent chemoradiotherapy
(CRT) in locally advanced head and neck cancer (LANHC). J Clin
Oncol. 30(Suppl): abstr 5501. 2012.
|
|
12
|
Haraf DJ, Rosen FR, Stenson K, et al:
Induction chemotherapy followed by concomitant TFHX
chemoradiotherapy with reduced dose radiation in advanced head and
neck cancer. Clin Cancer Res. 9:5936–5943. 2003.PubMed/NCBI
|
|
13
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010.PubMed/NCBI
|
|
15
|
Vermorken JB, Mesia R, Rivera F, et al:
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kies MS, Holsinger FC, Lee JJ, et al:
Induction chemotherapy and cetuximab for locally advanced squamous
cell carcinoma of the head and neck: results from a phase II
prospective trial. J Clin Oncol. 28:8–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wanebo HJ and Ghebremichael M, Burtness B,
Spencer S, Ridge J, Forastiere A and Ghebremichael M: Phase II
evaluation of cetuximab (C225) combined with induction paclitaxel
and carboplatin followed by C225, paclitaxel, carboplatin, and
radiation for stage III/IV operable squamous cancer of the head and
neck (ECOG, E2303). J Clin Oncol (ASCO Annual Meeting Proceedings
Part I) (Suppl). (18S): 60152007.
|
|
18
|
Seiwert TY, Haraf DJ, Cohen EE, et al: A
randomized phase II trial of cetuximab-based induction chemotherapy
followed by concurrent cetuximab, 5-FU, hydroxyurea, and
hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin,
and accelerated radiation with concomitant boost (CetuxPX) in
patients with locoregionally advanced head and neck cancer (HNC). J
Clin Oncol. 29:2011.(suppl; abstr 5519).
|
|
19
|
Forastiere AA, Goepfert H, Maor M, et al:
Concurrent chemotherapy and radiotherapy for organ preservation in
advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adelstein DJ, Moon J, Hanna E, et al:
Docetaxel, cisplatin, and fluorouracil induction chemotherapy
followed by accelerated fractionation/concomitant boost radiation
and concurrent cisplatin in patients with advanced squamous cell
head and neck cancer: A Southwest Oncology Group phase II trial
(S0216). Head Neck. 32:221–228. 2010.
|
|
21
|
Ang KK, Harris J, Wheeler R, et al: Human
papillomavirus and survival of patients with oropharyngeal cancer.
N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fakhry C, Westra WH, Li S, et al: Improved
survival of patients with human papillomavirus-positive head and
neck squamous cell carcinoma in a prospective clinical trial. J
Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lassen P, Eriksen JG, Hamilton-Dutoit S,
Tramm T, Alsner J and Overgaard J: Effect of HPV-associated
p16INK4A expression on response to radiotherapy and survival in
squamous cell carcinoma of the head and neck. J Clin Oncol.
27:1992–1998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weiss J: Induction Chemotherapy for
Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
http://clinicaltrials.gov/ct2/show/NCT01412229?term=jared+weiss&rank=2uri.
Accessed December 7, 2012.
|
